Atomoxetine Tablets

Utilized to manage attention deficit hyperactivity disorder and formulated to support cognitive regulation.

Strengths: 10 · 18 · 25mg

Medicine details

Alternative names

Strattera

Therapeutic class

Selective Noradrenaline Reuptake Inhibitor (SNRI)

Pharmacological class

Selective Noradrenaline Reuptake Inhibitor

Minor side effects

nausea; vomiting; fatigue; decreased appetite

Moderate side effects

abdominal pain; insomnia; dry mouth; irritability

Dosage forms

Tablet

Administration route

Oral use

Prescription status

POM

Manufacturer

Eli Lilly

Onset Time

2–4 weeks

Duration

24 hours

Storage instructions

Store below 25°C in a dry place, protected from light.

Drug interactions

monoamine oxidase inhibitors; salbutamol; antihypertensives

Age restrictions

Not recommended for children under six years of age.

Contraindications

hypersensitivity to atomoxetine; glaucoma; concurrent use of monoamine oxidase inhibitors; phaeochromocytoma

Precautions and warnings

monitor for emergent suicidal ideation; monitor heart rate and blood pressure; assess liver function if symptoms of jaundice occur

Serious side effects

suicidal ideation — requires immediate medical attention; hepatotoxicity — requires immediate medical attention; seizures — requires immediate medical attention; angioedema — requires immediate medical attention

Patient summary

Utilized to manage attention deficit hyperactivity disorder and formulated to support cognitive regulation.

Mechanism of action

Atomoxetine is a selective noradrenaline reuptake inhibitor. It works by increasing the levels of the neurotransmitter noradrenaline in the synaptic clefts, which helps improve attention, concentration, and impulse control in individuals with neurodevelopmental conditions.

Pregnancy and breastfeeding

Pregnancy: Use is not recommended unless clinically necessary. Breastfeeding: Caution is advised; consult a healthcare professional regarding potential risks.

Atomoxetine Tablets

Utilized to manage attention deficit hyperactivity disorder and formulated to support cognitive regulation.

Editorial Notes

  • Active ingredient(s): Atomoxetine
  • Listed indication(s): Attention Deficit Hyperactivity Disorder

Usually available as

  • 180 tablets - 10 mg1255-10-mg-14956
  • 60 tablets - 18 mg1255-18-mg-14970
  • 60 tablets - 25 mg1255-25-mg-14959